BlossomHill Therapeutics prices upsized $150m IPO on Nasdaq

BlossomHill Therapeutics has priced its initial public offering at $16.00 per share, raising $150 million gross from the sale of 9,375,000 shares of common stock. The offering was upsized ahead of pricing, and underwriters have a 30-day greenshoe option to purchase up to 1,406,250 additional shares, which could lift total gross proceeds to approximately $172.5 million. Shares are expected to begin trading on the Nasdaq Global Select Market on 7 August 2026 under the ticker "BLSM", with the offering due to close on 10 August, subject to customary conditions.

J.P. Morgan, Leerink Partners and Guggenheim Securities acted as lead book-running managers, with LifeSci Capital and H.C. Wainwright serving as joint book-running managers. The participation of Leerink and LifeSci, both specialist healthcare underwriters, reflects investor appetite for the story's scientific pedigree.

The pipeline

BlossomHill was founded and is led by J. Jean Cui, a medicinal chemist who the company credits with contributing to three FDA-approved drugs over her career. The company's approach centres on macrocyclic small molecule design, a chemistry discipline that can confer target selectivity and improved pharmacokinetics compared with more conventional scaffolds.

Its lead clinical asset, BH-30643, is a non-covalent, macrocyclic EGFR inhibitor designed to address the C797S resistance mutation that emerges after treatment with third-generation EGFR tyrosine kinase inhibitors such as osimertinib. That mutation represents a recognised and commercially significant unmet need in NSCLC: as osimertinib has become the dominant first- and second-line standard of care, the C797S-resistant population is growing, and no approved therapy currently addresses it directly. A second clinical programme, BH-30236, targets CLK kinase in relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndrome. A third asset, BH-501284, is a preclinical pan-KRAS Switch II inhibitor aimed at KRAS-mutant solid tumours.

Market context

BlossomHill's IPO arrives at a moment of recovering confidence in biotech public markets. After a prolonged period of subdued new listings, a string of oncology-focused flotations in the first half of 2026 demonstrated that investors would support differentiated clinical-stage stories, particularly those with resistance-mechanism hypotheses and founders with a track record of prior regulatory approvals.

The EGFR resistance field is competitive. A number of companies, including larger-capitalisation players and well-funded private biotechs, are pursuing fourth-generation EGFR inhibitors or combination strategies to tackle C797S. BlossomHill will need compelling early clinical data on response rate and intracranial activity, the latter being especially important because NSCLC brain metastases are common and osimertinib's CNS penetration has raised the bar. The company's macrocyclic, brain-active chemistry claim for BH-30643 is therefore a deliberate competitive signal, though clinical validation remains ahead.

The use of IPO proceeds was not broken out in detail in the pricing announcement; investors will look to the prospectus for a precise allocation across the three programmes. The greenshoe, if fully exercised, adds meaningful headroom, and a clean balance sheet at listing gives the company optionality on partnership terms as it reports early clinical data.